Women not receiving risedronate in stratum I and II who received anastrozole ( 310 women ) had a significant BMD decrease after 3 years of follow-up compared with women who received placebo ( 342 women ) at the lumbar spine ( -40 % [ -45 to -34 ] vs -12 % [ -17 to -07 ] , p < 00001 ) and total hip ( -40 % [ -44 to -36 ] vs -18 % [ -21 to -14 ] , p < 00001 ) .